

Daniel W Chan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11622777/daniel-w-chan-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

221
papers

18,929
citations

71
h-index

134
g-index

233
ext. papers

21,961
ext. citations

7.1
avg, IF

6.18
L-index

#	Paper	IF	Citations
221	MiCheck prostate blood test for aggressive prostate cancer designed for the clinical lab setting.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 229-229	2.2	
220	Improving the detection of aggressive prostate cancer using immunohistochemical staining of protein marker panels.. <i>American Journal of Cancer Research</i> , 2022 , 12, 1323-1336	4.4	
219	Validation of Serum Biomarkers That Complement CA19-9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays.. <i>Biomedicines</i> , 2021 , 9,	4.8	2
218	Proteogenomic and metabolomic characterization of human glioblastoma. <i>Cancer Cell</i> , 2021 , 39, 509-528.e20	24.3	71
217	A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer. <i>Theranostics</i> , 2021 , 11, 6214-6224	12.1	5
216	Detection of Uveal Melanoma by Multiplex Immunoassays of Serum Biomarkers. <i>Methods in Molecular Biology</i> , 2021 , 2265, 447-459	1.4	2
215	Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. <i>Cancer Cell</i> , 2021 , 39, 361-379.e16	24.3	50
214	A proteogenomic portrait of lung squamous cell carcinoma. <i>Cell</i> , 2021 , 184, 4348-4371.e40	56.2	15
213	Proteogenomic characterization of pancreatic ductal adenocarcinoma. <i>Cell</i> , 2021 , 184, 5031-5052.e26	56.2	26
212	Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 170	22.4	7
211	Tumor markers 2020 , 779-793		1
210	Orthogonal Proteomic Platforms and Their Implications for the Stable Classification of High-Grade Serous Ovarian Cancer Subtypes. <i>iScience</i> , 2020 , 23, 101079	6.1	10
209	Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. <i>Cell</i> , 2020 , 182, 200-225.e35	56.2	139
208	Development and evaluation of the MiCheck test for aggressive prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 683.e11-683.e18	2.8	3
207	Proteogenomic Characterization of Endometrial Carcinoma. <i>Cell</i> , 2020 , 180, 729-748.e26	56.2	122
206	Proteomic analysis of degradation ubiquitin signaling by ubiquitin occupancy changes responding to 26S proteasome inhibition. <i>Clinical Proteomics</i> , 2020 , 17, 2	5	6
205	An Integrated Workflow for Global, Glyco-, and Phospho-proteomic Analysis of Tumor Tissues. <i>Analytical Chemistry</i> , 2020 , 92, 1842-1849	7.8	11

204	A high-stringency blueprint of the human proteome. <i>Nature Communications</i> , 2020 , 11, 5301	17.4	59
203	Urinary glycoproteins associated with aggressive prostate cancer. <i>Theranostics</i> , 2020 , 10, 11892-11907	12.1	14
202	Proteomic Analysis of the Air-Way Fluid in Lung Cancer. Detection of Periostin in Bronchoalveolar Lavage (BAL). <i>Frontiers in Oncology</i> , 2020 , 10, 1072	5.3	2
201	Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma. <i>Cell Reports</i> , 2020 , 33, 108276	10.6	33
200	Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability. <i>Cell Reports Medicine</i> , 2020 , 1,	18	24
199	Validation of a novel model for the early detection of hepatocellular carcinoma. <i>Clinical Proteomics</i> , 2019 , 16, 2	5	14
198	Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities. <i>Cell</i> , 2019 , 177, 1035-1049.e19	56.2	237
197	Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA. <i>Clinical Proteomics</i> , 2019 , 16, 13	5	12
196	A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma. <i>Clinical Proteomics</i> , 2019 , 16, 10	5	19
195	Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): A critical step towards the personalized care of renal cancers. <i>Seminars in Cancer Biology</i> , 2019 , 55, 8-15	12.7	26
194	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. <i>Cell</i> , 2019 , 179, 964-983.e31	58.1	173
193	Cancer biomarker discovery and translation: proteomics and beyond. <i>Expert Review of Proteomics</i> , 2019 , 16, 93-103	4.2	54
192	Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 174-182	4	20
191	Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors. <i>Molecular and Cellular Proteomics</i> , 2019 , 18, 448-460	7.6	11
190	Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry. <i>Nature Protocols</i> , 2018 , 13, 1632-1661	18.8	176
189	Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. <i>JAMA Oncology</i> , 2017 , 3, 1085-1093	13.4	88
188	Cancer Biomarker Assays: Performance Standards 2017 , 267-276		
187	Protein signatures of molecular pathways in non-small cell lung carcinoma (NSCLC): comparison of glycoproteomics and global proteomics. <i>Clinical Proteomics</i> , 2017 , 14, 31	5	21

186	Multi-laboratory assessment of reproducibility, qualitative and quantitative performance of SWATH-mass spectrometry. <i>Nature Communications</i> , 2017 , 8, 291	17.4	252
185	Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues. <i>Journal of Proteome Research</i> , 2017 , 16, 4523-4530	5.6	14
184	An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors. <i>Clinical Proteomics</i> , 2017 , 14, 16	5	9
183	Proteome Profiling Outperforms Transcriptome Profiling for Coexpression Based Gene Function Prediction. <i>Molecular and Cellular Proteomics</i> , 2017 , 16, 121-134	7.6	67
182	Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. <i>BJU International</i> , 2017 , 120, 61-68	5.6	54
181	Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?. <i>Journal of Urology</i> , 2016 , 195, 330-6	2.5	10
180	Predicting Ovarian Cancer Patients' Clinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures. <i>Journal of Proteome Research</i> , 2016 , 15, 2455-65	5.6	28
179	Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. <i>Cell</i> , 2016 , 166, 755-765	56.2	544
178	Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides. <i>Nature Biotechnology</i> , 2016 , 34, 84-8	44.5	160
177	Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. <i>American Journal of Obstetrics and Gynecology</i> , 2016 , 215, 82.e1-82.e11	6.4	59
176	Reproducibility of Differential Proteomic Technologies in CPTAC Fractionated Xenografts. <i>Journal of Proteome Research</i> , 2016 , 15, 691-706	5.6	35
175	Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics Assays. <i>Methods in Molecular Biology</i> , 2016 , 1410, 223-36	1.4	25
174	Advances in mass spectrometry-based clinical biomarker discovery. <i>Clinical Proteomics</i> , 2016 , 13, 1	5	157
173	Precision medicine: from pharmacogenomics to pharmacoproteomics. <i>Clinical Proteomics</i> , 2016 , 13, 25	5	26
172	Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. <i>Journal of Urology</i> , 2015 , 194, 65-72	2.5	110
171	Multiplexed Targeted Mass Spectrometry-Based Assays for the Quantification of N-Linked Glycosite-Containing Peptides in Serum. <i>Analytical Chemistry</i> , 2015 , 87, 10830-8	7.8	25
170	Integrated glycoprotein immobilization method for glycopeptide and glycan analysis of cardiac hypertrophy. <i>Analytical Chemistry</i> , 2015 , 87, 9671-8	7.8	23
169	The prostate health index selectively identifies clinically significant prostate cancer. <i>Journal of Urology</i> , 2015 , 193, 1163-9	2.5	171

168	Tissue proteomics using chemical immobilization and mass spectrometry. <i>Analytical Biochemistry</i> , 2015 , 469, 27-33	3.1	17
167	Glycoproteins identified from heart failure and treatment models. <i>Proteomics</i> , 2015 , 15, 567-79	4.8	28
166	Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers. <i>Theranostics</i> , 2015 , 5, 267-76	12.1	53
165	Derivation of a second generation multivariate index assay to improve specificity in pre-surgical evaluation of adnexal masses for risk of ovarian malignancy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5561-5561 ¹	2.3	1
164	A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serum. <i>Journal of Proteome Research</i> , 2014 , 13, 875-82	5.6	51
163	Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2014 , 210, 78.e1-9	6.4	30
162	Can urinary PCA3 supplement PSA in the early detection of prostate cancer?. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4066-72	2.2	186
161	Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. <i>Molecular and Cellular Proteomics</i> , 2014 , 13, 1690-704	7.6	239
160	Biomarkers in prostate cancer: what's new?. <i>Current Opinion in Oncology</i> , 2014 , 26, 259-64	4.2	116
159	Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. <i>Clinical Proteomics</i> , 2013 , 10, 13	5	270
158	Analysis of serum protein glycosylation by a differential lectin immunosorbant assay (dLISA). <i>Clinical Proteomics</i> , 2013 , 10, 12	5	6
157	Retraction: Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 508	12.9	
156	Glycoproteomics using fluid-based specimens in the discovery of lung cancer protein biomarkers: promise and challenge. <i>Proteomics - Clinical Applications</i> , 2013 , 7, 55-69	3.1	10
155	Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass. <i>American Journal of Obstetrics and Gynecology</i> , 2013 , 209, 581.e1-8	6.4	13
154	Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. <i>Journal of Urology</i> , 2013 , 189, 1702-6	2.5	41
153	Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. <i>Gynecologic Oncology</i> , 2013 , 128, 252-9	4.9	84
152	The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. <i>Journal of Urology</i> , 2013 , 190, 70-6	2.5	35
151	Glycoproteomic analysis of bronchoalveolar lavage (BAL) fluid identifies tumor-associated glycoproteins from lung adenocarcinoma. <i>Journal of Proteome Research</i> , 2013 , 12, 3689-96	5.6	23

150	Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery. <i>Molecular and Cellular Proteomics</i> , 2013 , 12, 356-68	7.6	17
149	Analysis of N-glycoproteins using genomic N-glycosite prediction. <i>Journal of Proteome Research</i> , 2013 , 12, 5609-15	5.6	8
148	Integrated analyses of proteins and their glycans in a magnetic bead-based multiplex assay format. <i>Clinical Chemistry</i> , 2013 , 59, 315-24	5.5	12
147	A panel of biomarkers to improve specificity in presurgical assessment of adnexal masses for risk of ovarian malignancy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 5573-5573	2.2	
146	Updating risk prediction tools: a case study in prostate cancer. <i>Biometrical Journal</i> , 2012 , 54, 127-42	1.5	22
145	Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. <i>Journal of Proteomics</i> , 2012 , 75, 4747-57	3.9	42
144	Multi-center analytical performance evaluation of the Access Hybritech [®] p2PSA immunoassay. <i>Clinica Chimica Acta</i> , 2012 , 413, 1279-83	6.2	11
143	Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer. <i>Clinica Chimica Acta</i> , 2012 , 413, 1506-11	6.2	25
142	The human proteome - a scientific opportunity for transforming diagnostics, therapeutics, and healthcare. <i>Clinical Proteomics</i> , 2012 , 9, 6	5	37
141	Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. <i>Journal of Proteome Research</i> , 2012 , 11, 3986-95	5.6	49
140	Improvement and multicenter evaluation of the analytical performance of an automated chemiluminescent immunoassay for alpha fetoprotein. <i>International Journal of Biological Markers</i> , 2012 , 27, 39-46	2.8	5
139	Tumor Markers 2012 , 617-667		1
138	Exciting news from Clinical Proteomics. <i>Clinical Proteomics</i> , 2011 , 8, 3	5	
137	Aberrant glycosylation associated with enzymes as cancer biomarkers. <i>Clinical Proteomics</i> , 2011 , 8, 7	5	168
136	Tyramide signal amplification for antibody-overlay lectin microarray: a strategy to improve the sensitivity of targeted glycan profiling. <i>Journal of Proteome Research</i> , 2011 , 10, 1425-31	5.6	34
135	Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays. <i>Analytical Chemistry</i> , 2011 , 83, 8509-16	7.8	66
134	Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. <i>Analytical Chemistry</i> , 2011 , 83, 240-5	7.8	73
133	A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. <i>Journal of Urology</i> , 2011 , 185, 1650-5	2.5	322

132	A comparative evaluation of Golgi protein-73, fucosylated hemopexin, Fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011 , 49, 711-8	5.9	46
131	A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 1193-200	4	165
130	The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2995-9	4	146
129	Will Cancer Proteomics Suffer from Premature Death?. <i>Clinical Proteomics</i> , 2010 , 6, 1-3	5	7
128	A Targeted Proteomics Approach for Biomarker Discovery Using Bilateral Matched Nipple Aspiration Fluids. <i>Clinical Proteomics</i> , 2010 , 6, 57-64	5	
127	Decoding the Folding Patterns of Serum Proteins: An Alternative Strategy for Cancer Biomarker Validation?. <i>Clinical Proteomics</i> , 2010 , 6, 53-55	5	2
126	A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 73-86	4.4	12
125	Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. <i>Expert Opinion on Medical Diagnostics</i> , 2009 , 3, 597-605		46
124	Detection of Autoantibodies to Annexin A11 in Different Types of Human Cancer. <i>Clinical Proteomics</i> , 2009 , 5, 125-131	5	3
123	Targeted detection of prostate cancer proteins in serum using heavy-isotope-labeled-peptide standards and MALDI-TOF/TOF. <i>Proteomics - Clinical Applications</i> , 2009 , 3, 597-608	3.1	6
122	Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with Paclitaxel resistance. <i>Proteomics - Clinical Applications</i> , 2009 , 3, 1288-95	3.1	20
121	Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. <i>Journal of Proteome Research</i> , 2009 , 8, 113-7	5.6	449
120	Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. <i>Journal of Proteome Research</i> , 2009 , 8, 613-9	5.6	112
119	Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. <i>Journal of Urology</i> , 2009 , 181, 1407-14	2.5	35
118	Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. <i>Neoplasia</i> , 2009 , 11, 605-14, 1 p following 614	6.4	37
117	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. <i>Clinical Chemistry</i> , 2008 , 54, e1-e10	5.5	108
116	[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. <i>Journal of Urology</i> , 2008 , 180, 539-43; discussion 543	2.5	82
115	Prostate specific antigen assay standardization bias could affect clinical decision making. <i>Journal of Urology</i> , 2008 , 180, 1959-62; discussion 1962-3	2.5	21

114	Comparability of tumor marker immunoassays: still an important issue for clinical diagnostics?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008 , 46, 575-6	5.9	6
113	Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 1349-54	12.9	33
112	SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. <i>Clinical Chemistry</i> , 2008 , 54, 53-60	5.5	118
111	Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. <i>Clinical Chemistry</i> , 2008 , 54, 44-52	5.5	115
110	Mass Spectrometric Identification of Proteotypic Peptides from Clinically Used Tumor Markers. <i>Clinical Proteomics</i> , 2008 , 4, 58-66	5	4
109	National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. <i>Clinical Chemistry</i> , 2008 , 54, e11-79 ⁵	5.5	45 ¹
108	Biomarkers for Cancer Diagnostics 2008 , 277-282		1
107	Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. <i>Clinical Cancer Research</i> , 2007 , 13, 6842-9	12.9	34
106	Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. <i>Cancer Research</i> , 2007 , 67, 5600-5	10.1	40
105	EPCA-2: a highly specific serum marker for prostate cancer. <i>Urology</i> , 2007 , 69, 714-20	1.6	98
104	Enzymes and related proteins as cancer biomarkers: a proteomic approach. <i>Clinica Chimica Acta</i> , 2007 , 381, 93-7	6.2	47
103	Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. <i>Clinical Chemistry</i> , 2006 , 52, 1045-53 ⁵	5.5	88
102	Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. <i>Clinical Cancer Research</i> , 2006 , 12, 442-6	12.9	179
101	Validation of Breast Cancer Biomarkers Identified by Mass Spectrometry: Some of the authors of the article cited above respond:. <i>Clinical Chemistry</i> , 2006 , 52, 772-772	5.5	1
100	Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade. <i>Journal of Urology</i> , 2005 , 173, 752-6	2.5	21
99	The clinical application of proteomics. <i>Clinica Chimica Acta</i> , 2005 , 357, 151-8	6.2	60
98	Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. <i>International Journal of Cancer</i> , 2005 , 115, 783-9	7.5	153
97	HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. <i>Proteomics</i> , 2005 , 5, 3262-77	4.8	457

96	Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. <i>Proteomics</i> , 2005 , 5, 3467-74	4.8	88
95	Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. <i>Proteomics</i> , 2005 , 5, 3226-45	4.8	672
94	Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. <i>Clinical Cancer Research</i> , 2005 , 11, 8312-20	12.9	84
93	Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. <i>Clinical Chemistry</i> , 2005 , 51, 102-12	5.5	311
92	Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. <i>Clinical Chemistry</i> , 2005 , 51, 2229-35	5.5	147
91	Quality control for SELDI analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005 , 43, 125-6	5.9	10
90	Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. <i>Clinical Cancer Research</i> , 2004 , 10, 860-8	12.9	242
89	Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. <i>Cancer Research</i> , 2004 , 64, 5882-90	10.1	796
88	Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. <i>Clinical Cancer Research</i> , 2004 , 10, 2386-92	12.9	221
87	Cancer proteomics: Serum diagnostics for tumor marker discovery. <i>Annals of the New York Academy of Sciences</i> , 2004 , 1022, 286-94	6.5	50
86	Bioinformatics strategies for proteomic profiling. <i>Clinical Biochemistry</i> , 2004 , 37, 636-41	3.5	51
85	Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. <i>Journal of Urology</i> , 2004 , 171, 1782-7	2.5	55
84	Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. <i>Urology</i> , 2004 , 64, 1160-4	1.6	41
83	Characterization of renal allograft rejection by urinary proteomic analysis. <i>Annals of Surgery</i> , 2003 , 237, 660-4; discussion 664-5	7.8	107
82	A simple affinity spin tube filter method for removing high-abundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis. <i>Proteomics</i> , 2003 , 3, 243-8	4.8	104
81	Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. <i>Journal of Urology</i> , 2003 , 170, 1787-91	2.5	92
80	Comparison of total prostate-specific antigen and derivative levels in a screening population of black, white, and Korean-American men. <i>Clinical Prostate Cancer</i> , 2003 , 2, 173-6		3
79	Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer. <i>Urology</i> , 2003 , 62, 1058-62	1.6	8

78	Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. <i>Urology</i> , 2003 , 61, 274-6	1.6	94
77	Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. <i>Journal of Urology</i> , 2003 , 170, 723-6	2.5	72
76	Standardization of two immunoassays for human glandular kallikrein 2. <i>Clinical Chemistry</i> , 2003 , 49, 601-10	3.0	21
75	The application of clinical proteomics to cancer and other diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003 , 41, 1562-70	5.9	40
74	Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization (SELDI). <i>Reviews in Urology</i> , 2003 , 5, 81-9	1	3
73	HLA-G is a potential tumor marker in malignant ascites. <i>Clinical Cancer Research</i> , 2003 , 9, 4460-4	12.9	130
72	A new model ELISA, based on two monoclonal antibodies, for quantification of fatty acid synthase. <i>Journal of Immunoassay and Immunochemistry</i> , 2002 , 23, 279-92	1.8	7
71	Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men. <i>Urology</i> , 2002 , 60, 18-23	1.6	10
70	Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. <i>Urology</i> , 2002 , 60, 31-5	1.6	56
69	Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?. <i>Urology</i> , 2002 , 60, 36-41	1.6	11
68	Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. <i>Urology</i> , 2002 , 60, 10-7	1.6	20
67	Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer. <i>Clinica Chimica Acta</i> , 2002 , 326, 81-95	6.2	8
66	Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. <i>Journal of Urology</i> , 2002 , 167, 2017-23; discussion 2023-4	2.5	55
65	Clinical Evaluation of the Elecsys Total Prostate-specific Antigen Assay on the Elecsys 1010 and 2010 Systems. <i>Clinical Chemistry</i> , 2002 , 48, 944-947	5.5	9
64	Proteomic approaches to tumor marker discovery. <i>Archives of Pathology and Laboratory Medicine</i> , 2002 , 126, 1518-26	5	181
63	Proteomics and Bioinformatics Approaches for Identification of Serum Biomarkers to Detect Breast Cancer. <i>Clinical Chemistry</i> , 2002 , 48, 1296-1304	5.5	606
62	Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. <i>Cancer Research</i> , 2002 , 62, 1868-75	10.1	204
61	Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. <i>Clinical Chemistry</i> , 2002 , 48, 1296-304	5.5	197

60	PLASMA SELENIUM LEVEL BEFORE DIAGNOSIS AND THE RISK OF PROSTATE CANCER DEVELOPMENT. <i>Journal of Urology</i> , 2001 , 166, 2034-2038	2.5	182
59	Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. <i>Cancer Letters</i> , 2001 , 167, 99-104	9.9	80
58	Two-site ELISA for the quantitative determination of fatty acid synthase. <i>Clinica Chimica Acta</i> , 2001 , 304, 107-115	6.2	27
57	Cardiac troponin T and C-reactive protein as markers of acute cardiac allograft rejection. <i>Clinica Chimica Acta</i> , 2001 , 312, 31-9	6.2	25
56	Immunosensors--principles and applications to clinical chemistry. <i>Clinica Chimica Acta</i> , 2001 , 314, 1-26	6.2	586
55	Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. <i>Urology</i> , 2001 , 57, 707-11	1.6	25
54	Hybritech Total and Free Prostate-specific Antigen Assays Developed for the Beckman Coulter Access Automated Chemiluminescent Immunoassay System: A Multicenter Evaluation of Analytical Performance. <i>Clinical Chemistry</i> , 2001 , 47, 129-132	5.5	24
53	Assessing tumors in living animals through measurement of urinary beta-human chorionic gonadotropin. <i>Nature Medicine</i> , 2000 , 6, 711-4	50.5	31
52	Myoglobin for early risk stratification of emergency department patients with possible myocardial ischemia. <i>Academic Emergency Medicine</i> , 2000 , 7, 625-36	3.4	4
51	WHO First International Standards for Prostate-specific Antigen: The Beginning of the End for Assay Discrepancies?. <i>Clinical Chemistry</i> , 2000 , 46, 1291-1292	5.5	23
50	CK-MB isoforms for early risk stratification of emergency department patients. <i>Clinica Chimica Acta</i> , 2000 , 300, 57-73	6.2	3
49	Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. <i>Urology</i> , 2000 , 55, 909-14	1.6	21
48	COMPLEXED PROSTATE SPECIFIC ANTIGEN PROVIDES SIGNIFICANT ENHANCEMENT OF SPECIFICITY COMPARED WITH TOTAL PROSTATE SPECIFIC ANTIGEN FOR DETECTING PROSTATE CANCER. <i>Journal of Urology</i> , 2000 , 163, 1476-1480	2.5	118
47	Redesigned proficiency testing materials improve survey outcomes for prostate-specific antigen. A College of American Pathologists Ligand Assay Survey tool. <i>Archives of Pathology and Laboratory Medicine</i> , 2000 , 124, 1608-13	5	8
46	Analytical and Clinical Performance Characteristics of Hybritech Tandem-R free PSA Assay during a Large Multicenter Clinical Trial to Determine the Clinical Utility of Percentage of Free Prostate-specific Antigen. <i>Clinical Chemistry</i> , 1999 , 45, 1863-1865	5.5	6
45	Prostate-specific Antigen: Advances and Challenges. <i>Clinical Chemistry</i> , 1999 , 45, 755-756	5.5	8
44	Critical analysis of false elevations in PSA results reported with the Abbott AxSYM assay. <i>Prostate</i> , 1999 , 38, 79-80	4.2	
43	Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. <i>Urology</i> , 1999 , 54, 220-4	1.6	99

42	Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. <i>Urology</i> , 1999 , 54, 839-45	1.6	107
41	Clinical analyzers. Immunoassays. <i>Analytical Chemistry</i> , 1999 , 71, 356R-362R	7.8	26
40	The prognostic significance of troponin I and troponin T. <i>Academic Emergency Medicine</i> , 1998 , 5, 758-67	3.4	20
39	Bayer Immuno 1 PSA Assay: an automated, ultrasensitive method to quantitate total PSA in serum. <i>Journal of Clinical Laboratory Analysis</i> , 1998 , 12, 65-74	3	8
38	Use of troponin T and creatine kinase-MB subunit levels for risk stratification of emergency department patients with possible myocardial ischemia. <i>Annals of Emergency Medicine</i> , 1998 , 31, 19-29	2.1	40
37	INFLUENCE OF RADICAL PROSTATECTOMY ON SERUM HORMONE LEVELS. <i>Journal of Urology</i> , 1998 , 160, 449-453	2.5	143
36	NONPALPABLE STAGE T1C PROSTATE CANCER: PREDICTION OF INSIGNIFICANT DISEASE USING FREE/TOTAL PROSTATE SPECIFIC ANTIGEN LEVELS AND NEEDLE BIOPSY FINDINGS. <i>Journal of Urology</i> , 1998 , 160, 2407-2411	2.5	219
35	THE USE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN FOR STAGING CLINICALLY LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 1998 , 159, 1238-1242	2.5	89
34	Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. <i>Journal of Urology</i> , 1998 , 159, 449-53	2.5	50
33	Analytical and clinical evaluation of an electrochemiluminescence immunoassay for the determination of CA 125. <i>Clinical Chemistry</i> , 1998 , 44, 2530-2536	5.5	28
32	Serum concentrations of cardiac troponin I in sudden death: a pilot study. <i>American Journal of Forensic Medicine and Pathology</i> , 1998 , 19, 324-8	1	33
31	THE USE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN FOR STAGING CLINICALLY LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 1998 , 1238-1242	2.5	4
30	INFLUENCE OF RADICAL PROSTATECTOMY ON SERUM HORMONE LEVELS. <i>Journal of Urology</i> , 1998 , 449-453	2.5	5
29	NONPALPABLE STAGE T1C PROSTATE CANCER. <i>Journal of Urology</i> , 1998 , 2407-2411	2.5	11
28	Bayer immuno 1PSA assay: An automated, ultrasensitive method to quantitate total PSA in serum 1998 , 12, 65		2
27	Prostate-specific antigen. Its discovery and biochemical characteristics. <i>Urologic Clinics of North America</i> , 1997 , 24, 253-9	2.9	38
26	Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. <i>Urology</i> , 1997 , 49, 379-84	1.6	80
25	Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. <i>Urology</i> , 1997 , 50, 715-21	1.6	30

24	Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer. <i>World Journal of Urology</i> , 1997 , 15, 373-7	4	22
23	Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. <i>Urology</i> , 1996 , 48, 4-9	1.6	54
22	The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. <i>Urology</i> , 1996 , 48, 51-4	1.6	51
21	Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. <i>Urology</i> , 1996 , 48, 55-61	1.6	192
20	Clearance rate of serum-free and total PSA following radical retropubic prostatectomy. <i>Prostate</i> , 1996 , 29, 35-39	4.2	28
19	Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. <i>Prostate</i> , 1995 , 27, 25-31	4.2	107
18	Elevated serum human chorionic gonadotropin as evidence of secretory response in severe preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 1994 , 170, 1135-8	6.4	82
17	Breast cancer marker Ca549. A multicenter study. <i>American Journal of Clinical Pathology</i> , 1994 , 101, 465-70	7	7
16	Elevated circulating thrombomodulin in severe preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 1993 , 169, 148-9	6.4	68
15	The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. <i>Journal of Urology</i> , 1993 , 150, 110-4	2.5	979
14	The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer. <i>Journal of Urology</i> , 1992 , 148, 1832-4	2.5	31
13	Hepatitis B and hepatitis C in emergency department patients. <i>New England Journal of Medicine</i> , 1992 , 326, 1399-404	59.2	245
12	The potential utility of a rapid CK-MB assay in evaluating emergency department patients with possible myocardial infarction. <i>Annals of Emergency Medicine</i> , 1991 , 20, 954-60	2.1	34
11	Capillary prolactin measurement for diagnosis of seizures. <i>Annals of Neurology</i> , 1991 , 29, 187-90	9.4	38
10	Variants of prostate-specific antigen separated by concanavalin A. <i>Clinical Chemistry</i> , 1991 , 37, 1133-1134	4.5	17
9	Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. <i>Journal of Urology</i> , 1990 , 143, 747-52	2.5	516
8	The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. <i>Journal of Urology</i> , 1990 , 144, 1167-70; discussion 1170-1	2.5	34
7	The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. <i>Journal of Urology</i> , 1989 , 141, 987-92	2.5	111

6	Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. <i>Journal of Urology</i> , 1988 , 139, 766-72	2.5	532
5	General Principle of Immunoassay 1987 , 1-23		4
4	Endocrine Assays in the Monitoring of Pregnancy. <i>Clinics in Laboratory Medicine</i> , 1981 , 1, 157-179	2.1	
3	The chemistry of human transcortin. The effects of pH, urea, salt, and temperature on the binding of cortisol and progesterone. <i>Archives of Biochemistry and Biophysics</i> , 1977 , 182, 437-42	4.1	17
2	Orthogonal proteomic platforms and their implications for the stable classification of high-grade serous ovarian cancer subtypes		2
1	Multi-laboratory assessment of reproducibility, qualitative and quantitative performance of SWATH-mass spectrometry		3